top of page
The latest on cardiometabolic disease and Covid-19
Search
Experimental treatments and controversies, a review
Quality of evidence: C Controversial treatments: an updated understanding of the Coronavirus Disease 2019 Authors: Zhang C et al Journal:...
Abderrahim Benmoussa, phD
Apr 7, 20202 min read
Heparin and mortality in patients with coagulopathy, a retrospective cohort study
Quality of evidence: B- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with...
Abderrahim Benmoussa, phD
Apr 7, 20201 min read
Early use of short term corticosteroids therapy, an open-label non-randomized monocentric trial
Quality of evidence: C- Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19...
Abderrahim Benmoussa, phD
Apr 6, 20201 min read
Anti-inflammatory drugs and severe cases, a review, and expert position from China
Quality of evidence: C+ The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19):...
Abderrahim Benmoussa, phD
Apr 6, 20201 min read
Management of critically ill adults, a guideline summary for practioners
Quality of evidence: B- Management of Critically Ill Adults With COVID-19 Authors: Poston JT et al. Journal: JAMA Objectives: Centralize...
Abderrahim Benmoussa, phD
Apr 6, 20201 min read
Treatment of COVID-19-induced myocarditis in a young adult, a case report
Quality of evidence: D Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin Authors: Hu H et al Journal: ...
Abderrahim Benmoussa, phD
Apr 5, 20201 min read
QT and Hydroxychloroquine/Azithromycin, a retrospective cohort study
Strength of evidence: C+ The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin Authors:...
Abderrahim Benmoussa, phD
Apr 5, 20201 min read
Danger of Angiotensin receptor-blockers ? A letter to the editor
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Abderrahim Benmoussa, phD
Apr 5, 20201 min read
bottom of page